Roscovitine regulates invasive breast cancer cell (MDA-MB231) proliferation and survival through cell cycle regulatory protein cdk5

Experimental and Molecular Pathology

Volumn 82, Issue 1, 2007, Pages 25-32

  Goodyear, Shaun ^a   Sharma, Mahesh C ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; cdk5 p35; Cell cycle; Olomoucine; Roscovitine

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 5; OLOMOUCINE; PROTEIN P25; PROTEIN P35; ROSCOVITINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER INVASION; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME REGULATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; REGULATORY MECHANISM; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE 5; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; NERVE TISSUE PROTEINS; PURINES;

EID: 33845915536     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2006.09.002     Document Type: Article

References (37)

1. Baldin V., Lukas J., Marcote M.J., Pagano M., and Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 7 (1993) 812-821
2. Chae T., Kwon Y.T., Bronson R., Dikkes P., Li E., and Tsai L.H. Mice lacking p35, a neuronal specific activator of Cdk5, display cortical lamination defects, seizures, and adult lethality. Neuron 18 (1997) 29-42
3. Cowley S., Paterson H., Kemp P., and Marshall C.J. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77 (1994) 841-852
4. Davidson D.J., Haskell C., Majest S., Kherzai A., Egan D.A., Walter K.A., Schneider A., Gubbins E.F., Solomon L., Chen Z., Lesniewski R., and Henkin J. Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78. Cancer Res. 65 (2005) 4663-4672
5. Dong Y., Ganther H.E., Stewart C., and Ip C. Identification of molecular targets associated with selenium-induced growth inhibition in human breast cells using cDNA microarrays. Cancer Res. 62 (2002) 708-714
6. Elstner E., Linker-Israeli M., Said J., Umiel T., de Vos S., Shintaku I.P., Heber D., Binderup L., Uskokovic M., and Koeffler H.P. 20-epi-vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res. 55 (1995) 2822-2830
7. Freeman R.S., Estus S., and Johnson Jr. E.M. Analysis of cell cycle-related gene expression in postmitotic neurons: selective induction of Cyclin D1 during programmed cell death. Neuron 12 (1994) 343-355
8. Garrett M.D., and Fattaey A. CDK inhibition and cancer therapy. Curr. Opin. Genet. Dev. 9 (1999) 104-111
9. Havlicek L., Hanus J., Vesely J., Leclerc S., Meijer L., Shaw G., and Strnad M. Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J. Med. Chem. 40 (1997) 408-412
10. Jeffrey P.D., Russo A.A., Polyak K., Gibbs E., Hurwitz J., Massague J., and Pavletich N.P. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 376 (1995) 313-320
11. Kornberg L., Earp H.S., Parsons J.T., Schaller M., and Juliano R.L. Cell adhesion or integrin clustering increases phosphorylation of a focal adhesion-associated tyrosine kinase. J. Biol. Chem. 267 (1992) 23439-23442
12. Lees E. Cyclin dependent kinase regulation. Curr. Opin. Cell Biol. 7 (1995) 773-780
13. Lin H., Juang J.L., and Wang P.S. Involvement of Cdk5/p25 in digoxin-triggered prostate cancer cell apoptosis. J. Biol. Chem. 279 (2004) 29302-29307
14. Meijer L. Chemical inhibitors of cyclin-dependent kinases. Trends Cell Biol. 6 (1996) 393-397
15. Meijer L., Guidet S., and Vogel L. Progress in Cell Cycle Research (1996) (New York)
16. Meijer L., Borgne A., Mulner O., Chong J.P., Blow J.J., Inagaki N., Inagaki M., Delcros J.G., and Moulinoux J.P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243 (1997) 527-536
17. Meijer L., Leclerc S., and Leost M. Properties and potential-applications of chemical inhibitors of cyclin-dependent kinases [in process citation]. Pharmacol. Ther. 82 (1999) 279-284
18. Menck H.R., Jessup J.M., Eyre H.J., Cunningham M.P., Fremgen A., Murphy G.P., and Winchester D.P. Clinical highlights from the National Cancer Data Base: 1997. CA Cancer J. Clin. 47 (1997) 161-170
19. Mgbonyebi O.P., Russo J., and Russo I.H. Roscovitine inhibits the proliferative activity of immortal and neoplastic human breast epithelial cells. Anticancer Res. 18 (1998) 751-755
20. Mgbonyebi O.P., Russo J., and Russo I.H. Roscovitine induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells. Cancer Res. 59 (1999) 1903-1910
21. Negash S., Wang H.S., Gao C., Ledee D., and Zelenka P. Cdk5 regulates cell-matrix and cell-cell adhesion in lens epithelial cells. J. Cell Sci. 115 (2002) 2109-2117
22. Nguyen M., Watanabe H., Budson A.E., Richie J.P., Hayes D.F., and Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J. Natl. Cancer Inst. 86 (1994) 356-361
23. Nikolic M., Dudek H., Kwon Y.T., Ramos Y.F., and Tsai L.H. The cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation. Genes Dev. 10 (1996) 816-825
24. Ohshima T., Ward J.M., Huh C.G., Longenecker G., Pant H.C., Brady R.O., Martin L.J., and Kulkarni A.B. Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 11173-11178
25. Ohshima T., Gilmore E.C., Longenecker G., Jacobowitz D.M., Brady R.O., Herrup K., and Kulkarni A.B. Migration defects of cdk5(-/-) neurons in the developing cerebellum is cell autonomous. J. Neurosci. 19 (1999) 6017-6026
26. Pearson G., Robinson F., Beers Gibson T., Xu B.E., Karandikar M., Berman K., and Cobb M.H. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev. 22 (2001) 153-183
27. Pippin J.W., Qu Q., Meijer L., and Shankland S.J. Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with roscovitine, a novel cyclin-dependent kinase antagonist. J. Clin. Invest. 100 (1997) 2512-2520
28. Plate K.H., Breier G., Weich H.A., and Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359 (1992) 845-848
29. Schutte B., Nieland L., van Engeland M., Henfling M.E., Meijer L., and Ramaekers F.C. The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics. Exp. Cell Res. 236 (1997) 4-15
30. Sharma M., Sharma P., and Pant H.C. CDK-5-mediated neurofilament phosphorylation in SHSY5Y human neuroblastoma cells. J. Neurochem. 73 (1999) 79-86
31. Sharma P., Veeranna, Sharma M., Amin N.D., Sihag R.K., Grant P., Ahn N., Kulkarni A.B., and Pant H.C. Phosphorylation of MEK1 by cdk5/p35 down-regulates the mitogen-activated protein kinase pathway. J. Biol. Chem. 277 (2002) 528-534
32. Sharma M.R., Tuszynski G.P., and Sharma M.C. Angiostatin-induced inhibition of endothelial cell proliferation/apoptosis is associated with the down-regulation of cell cycle regulatory protein cdk5. J. Cell. Biochem. 91 (2004) 398-409
33. Sherr C.J. G1 phase progression: cycling on cue. Cell 79 (1994) 551-555
34. Sherr C.J. Cancer cell cycles. Science 274 (1996) 1672-1677
35. Tsai L.H., Delalle I., Caviness Jr. V.S., Chae T., and Harlow E. p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 371 (1994) 419-423
36. Vesely J., Havlicek L., Strnad M., Blow J.J., Donella-Deana A., Pinna L., Letham D.S., Kato J., Detivaud L., Leclerc S., et al. Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem. 224 (1994) 771-786
37. Wesierska-Gadek J., Gueorguieva M., Wojciechowski J., and Horky M. Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by roscovitine and olomoucine. Pol. J. Pharmacol. 56 (2004) 635-641